上海谊众(688091.SH)：上半年净利润3800.38万元 同比增长10.13%

Core Viewpoint - Shanghai Yizhong (688091.SH) reported significant growth in its core product, paclitaxel micelles, with sales increasing approximately 487% year-on-year, indicating strong market demand and operational performance [1] Financial Performance - The company achieved operating revenue of 160.31 million yuan, representing a year-on-year increase of 31.48% [1] - Net profit attributable to shareholders reached 38.00 million yuan, reflecting a year-on-year growth of 10.13% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 37.06 million yuan, which is an increase of 11.74% compared to the same period last year [1]